Bipolar affective disorder---left out in the cold
- 12 January 2002
- Vol. 324 (7329) , 61-62
- https://doi.org/10.1136/bmj.324.7329.61
Abstract
Footnotes RM has received funding from several pharmaceutical companies (AstraZeneca, GlaxoWellcome, SmithKline Beecham, Lilly, Lundbeck, Pfizer and Wyeth) for attending symposiums, speaking, or organising educational meetings about mood disorders. RM is also a member of the NHS executive North West mental health taskforce to implement the national strategic framework for mental health. MM is a member of the serious mental illness project group at the Department of Health. AH is a research psychologist employed by a national user charity (Manic Depression Fellowship) for people with bipolar affective disorder.Keywords
This publication has 7 references indexed in Scilit:
- The Lifetime Cost of Bipolar Disorder in the USPharmacoEconomics, 2001
- Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapyBiological Psychiatry, 2000
- Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatmentBMJ, 1999
- Lithium treatment and risk of suicidal behavior in bipolar disorder patients.The Journal of Clinical Psychiatry, 1998
- Relapse and impairment in bipolar disorderAmerican Journal of Psychiatry, 1995
- Lithium treatment: prescribing and monitoring habits in hospital and general practice.BMJ, 1992
- The Genetics of Depression and Manic-Depressive DisorderThe British Journal of Psychiatry, 1989